Beijing Chao Yang Hospital

bjcyh.com.cn

Total trials

126

Active

32

Phase 3

3

Total enrollment

43,747

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 9 of 9 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Dexmedetomidine prolonged sedation1
0.9% saline1
Aspirin1
Semaglutide Subcutaneous1
Semaglutide1
Immunotherapy1
Nafamostat1
Heparin1
Multicomponent frailty intervention1

Next readouts

  • 2023-12-30
  • 2026-08-01
  • 2026-12
  • 2026-12-31
  • 2027-01-01
  • 2027-09-30
  • 2027-12-31

Top conditions

  • Type 2 Diabetes6
  • Pulmonary Embolism6
  • Acute Respiratory Distress Syndrome5
  • Rectal Cancer4
  • Obesity3
  • Acute Exacerbation of Chronic Obstructive Pulmonary Disease3
  • Postoperative Delirium3
  • Thromboembolism3

Frequently asked questions about Beijing Chao Yang Hospital

How many clinical trials does Beijing Chao Yang Hospital have on ClinicalTrials.gov?
Beijing Chao Yang Hospital is listed as the lead sponsor on 126 clinical trials in ClinicalTrials.gov, 32 of which are currently active (recruiting, enrolling, or ongoing).
How many of Beijing Chao Yang Hospital's trials are in Phase 3?
3 of Beijing Chao Yang Hospital's trials are in Phase 3, spread across 9 active drug programs.
What therapeutic areas does Beijing Chao Yang Hospital focus on?
Beijing Chao Yang Hospital's most-studied conditions on ClinicalTrials.gov are Type 2 Diabetes, Pulmonary Embolism, Acute Respiratory Distress Syndrome, Rectal Cancer, Obesity.
When are Beijing Chao Yang Hospital's next clinical trial readouts?
Beijing Chao Yang Hospital has 7 upcoming primary-completion readouts tracked here; the soonest is “Camrelizumab Combined With Neoadjuvant Chemotherapy After Stent Placement for Left-Sided Obstructive Colonic Cancer”, expected around 2023-12-30.